Physician profile
David Herman
NPI 1326014390
$4,185.78
in general payments reported to CMS, 2019-2025
21 companies · $783 in 2025
The $783 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $421 · 2021: $486 · 2022: $356 · 2023: $700 · 2024: $857 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Education: $19.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.46 |
| Education | $19.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,072.98 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $675.52 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $397.77 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $352.34 | 2019-2025 | |
| Shionogi INC | $284.28 | 2024-2025 | Fetroja |
| Melinta Therapeutics, LLC | $244.23 | 2023-2025 | Rezzayo, Kimyrsa, Vabomere |
| Insmed, INC. | $222.39 | 2021-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $209.00 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $125.06 | 2020 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Heraeus Medical, LLC. | $124.09 | 2021 | |
| Organogenesis INC. | $119.80 | 2024 | |
| Theratechnologies INC. | $49.19 | 2022-2025 | Egrifta, Trogarzo |
| Pfizer INC. | $32.31 | 2024-2025 | |
| Janssen Products, Lp | $28.99 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Nabriva Therapeutics, Plc | $25.56 | 2021-2022 | |
| Allergan, INC. | $22.42 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.02 | 2024 | Vibativ |
| Emd Serono, INC. | $15.82 | 2024 | |
| Smith+Nephew, INC. | $14.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.